Skip to main content
SpringerLink
Log in

Immunosuppression and oncology

  • Chapter
Supportive therapy in haematology

  • 92 Accesses

Abstract

The study of the interaction between the host and the neoplastic cell is of fundamental importance in oncology. The topic has been frequently reviewed, so that the present chapter need only review the reviews, highlighting conclusions which are clinically relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Spector BD, Perry GS III, Kersey JH: Genetically determined immunodeficiency diseases and malignancy: Report for the immunodeficiency — Cancer Registry. Clin Immunol Immunopathol, 1978; 11: 12–29.

    Article  PubMed  CAS  Google Scholar 

  2. Melief CJM, Schwartz RS: Immunocompetence and malignancy. In Cancer: A comprehensive treatise. Becker FF (ed). New York, Plenum Press, 1975: 121–60.

    Google Scholar 

  3. Kersey JH, Spector BD, Good RA. Immunodeficiency and cancer. Advances Cancer Res, 1973; 18: 211–30.

    Article  CAS  Google Scholar 

  4. Congress of the United States: Review of the public health service’s response to AIDS. A technical memorandum. Office of Technology Assessment, Washington D.C., 1985.

    Google Scholar 

  5. Reed DM: On the pathological changes in Hodgkin’s disease with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rev, 1902; 10: 133–96.

    Google Scholar 

  6. Young RC, Corder MP, Haynes MA, DeVita VT: Delayed hypersensitivity in Hodgkin’s disease. Am J Med, 1972; 52: 63–72.

    Article  PubMed  CAS  Google Scholar 

  7. Eltringham JR, Kaplan HS: Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkin’s disease. Natl Cancer Inst Monograph, 1973; 36: 107–15.

    CAS  Google Scholar 

  8. Brown RS, Haynes HA, Foley HT, Goodwin HA, Berard CW, Carbone PP: Hodgkins’ disease. Immunologic clinical and histologic features of 50 untreated patients. Ann Intern Med, 1967; 67: 291–302.

    PubMed  CAS  Google Scholar 

  9. Kelly WD, Good RA, Varco RL, Levitt M: The altered response to skin monografts and to delayed allergens in Hodgkin’s disease. Surg Forum, 1958; 9: 785–89.

    PubMed  CAS  Google Scholar 

  10. Levy R, Kaplan HS: Impaired lymphocyte function in untreated Hodgkin’s disease. N Engl J Med, 1974; 290: 181–86.

    Article  PubMed  CAS  Google Scholar 

  11. Kaplan HS: Hodgkin’s Disease. 2nd edn. Cambridge, Mass, Harvard University Press, 1980.

    Google Scholar 

  12. Fuks Z, Strober S, Kaplan HS: Interaction between serum factors and T lymphocytes in Hodgkin’s disease: use as a diagnostic test. N Engl J Med, 1976; 295: 1273–78.

    Article  PubMed  CAS  Google Scholar 

  13. Posner MR, Reinherz EL, Breard J, Nadler LM, Rosenthal DS, Schlossman SF: Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin’s disease. Cancer, 1978; 48: 1170–76.

    Article  Google Scholar 

  14. De Sousa M, Smithyman A, Tan C: Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for non-binding proteins in the control of lymphoid cell migration. Am J Pathol, 1978; 90: 497–520.

    PubMed  Google Scholar 

  15. Jones SE, Griffith K, Dombrowski P, Gaines JA: Immunodeficiency in patients with non-Hodgkin’s lymphomas. Blood, 1977; 49: 335–44.

    PubMed  CAS  Google Scholar 

  16. Advani SH, Dinshaw KA, Nair CN, Gopal R, Talwalkar GV, Iyyer YS, Bhatia HM, Desai PB: Immune dysfunction in non-Hodgkin’s lymphoma. Cancer, 1980; 45: 2843–48.

    Article  PubMed  CAS  Google Scholar 

  17. Nedelkova M, Bacalova S, Georgiera B: Infectious complications and host immune defence in acute leukaemia. Eur J Cancer, 1981; 17: 617–22.

    PubMed  CAS  Google Scholar 

  18. Kay NE, Howe RB, Douglas SD: Effect of therapy on T cell subpopulations in patients with chronic lymphocytic leukaemia. Leuk Res, 1982; 6: 345–48.

    Article  PubMed  CAS  Google Scholar 

  19. Eilber FR, Morton DL: Impaired immunological reactivity and recurrence following cancer surgery. Cancer, 1970; 25: 362–67.

    Article  PubMed  CAS  Google Scholar 

  20. Oldham RK, Weese JL, Herberman RB, Perlin E. Mills M, Heims W, Blom J, Green D, Reid J, Bellinger S, Law I, McCoy JK, Dean JH, Cannon GB, Dieu I: Immunological monitoring and immunotherapy of carcinoma of the lung. Int J Cancer, 1976; 18: 739–49.

    Article  Google Scholar 

  21. Mier A, Stein JA, Ben-Efraim S: Immunocompetence, immunosuppression and human breast cancer. Cancer, 1980; 45: 2061–73.

    Article  Google Scholar 

  22. Cobleigh MA, Braun DP, Harris JE: Quantitation of lymphocytes and T cell subsets in patients with disseminated cancer. J Natl Cancer Inst, 1980; 64: 1041–45.

    PubMed  CAS  Google Scholar 

  23. Mandell GL, Fisher RI, Bostick F, Young RC: Ovarian cancer: a solid tumour with evidence of normal cellular immune function but abnormal B cell function. Am J Med, 1979; 66: 621–24.

    Article  PubMed  CAS  Google Scholar 

  24. Krishnan EC, Menon CD, Krishnan L, Jewell WR: Deficiency in maturation process of macrophages in human cancer. J Natl Cancer Inst, 1980; 65: 273–76.

    PubMed  CAS  Google Scholar 

  25. Snyderman R, Meadows L, Holder W, Wells S Jr: Abnormal monocyte chemotaxis in patients with breast cancer: Evidence for a tumour-mediated effect. J Natl Cancer Inst, 1978; 60: 737–40.

    PubMed  CAS  Google Scholar 

  26. Blomgren H, Berg R, Wasserman J, Glas U: Effect of radiotherapy on blood lymphocyte population in mammary carcinoma. Int J Oncol Biol Phys, 1976; 1: 177–88.

    Article  CAS  Google Scholar 

  27. Stjernsward J, Jondal M, Vanky F, Wigzell H, Sealy R: Lymphopenia and change in distribution of human B–T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet, 1972; 1: 1152–56.

    Google Scholar 

  28. Slade MS, Simmons RL, Yunis E, Greenberg LJ: Immunodepression after major surgery in normal patients. Surgery, 1975; 78: 363–72.

    PubMed  CAS  Google Scholar 

  29. Yew FH, Johnson RT: Human B and T lymphocytes differ in UV induced repair capacity. Exp Cell Res, 1978; 113: 227–31.

    Article  PubMed  CAS  Google Scholar 

  30. Fauci AS: Glucocortoid effects on circulating human mononuclear cells. J Reticuloendothelia Soc, 1979; 26: 727–38.

    CAS  Google Scholar 

  31. Baum M: Effect of administered hormones on the immune reaction. In: Host Defence in Breast Cancer, Stoll BA (ed). London, Heineman, 1975: 130–46.

    Google Scholar 

  32. Heppner GH, Calabresi P: Effect of sequence of administration of methotrexate, leucovorin and 5 fluorouracil on mammary tumour growth and survival in syngeneic C3H mice. Cancer Res, 1977; 37: 4580–83.

    PubMed  CAS  Google Scholar 

  33. Braun DP, Cobleigh MA, Harris JE: The `rebound overshoot’ phenomenon. A consequence of selective cytotoxic drug effect on immunoregulatory suppression mechanisms. Proc Am Soc Clin Oncol, 1980; 21: 373.

    Google Scholar 

  34. Garber M, Andresi D, Pioch Y, Radal M, Serou B Effect of cyclophosphamide and methylprednisolone on in vitro cellular immune response to allogeneic tumour cells. Correlation with in vivo rejection. Transplantation, 1978; 26: 142–49.

    Article  Google Scholar 

  35. Hosea SW, Burch GG, Broun EJ, Berg RA, Frank MM: Impaired immune response of splenectomised patients in polyvalent pneumococcal vaccine. Lancet, 1981; 1: 804–7.

    Article  PubMed  CAS  Google Scholar 

  36. Baumgartner JD, Glauser MP, Burgo-Black AL, Black RD, Pyndiah N, Chiolero R: Severe cytomegalovirus infection in multiply transfused splenectomised trauma patients. Lancet, 1982; ii: 63–65.

    Google Scholar 

  37. Stone HH, Stanley DG, Dejarness HH: Postsplenectomy viral hepatitis. JAMA, 1967; 199: 851–53.

    Article  PubMed  CAS  Google Scholar 

  38. Goffinet DR, Glastein EJ, Merigan TC: Herpes zostervaricella infections and lymphoma. Ann Intern Med, 1972; 76: 235–40.

    PubMed  CAS  Google Scholar 

  39. Monfardini S, Bajetta E, Arnold CA, Kenda R, Bona-donna G: Herpes zoster-varicella infection in malignant lymphomas. Influence of splenectomy and intensive treatment. Eur J Cancer, 1975; 11: 51–57.

    PubMed  CAS  Google Scholar 

  40. Rebout F, Donaldson SS, Kaplan HS: Herpes zoster and varicella infection in children with Hodgkin’s disease. Cancer, 1978; 41: 95–99.

    Article  Google Scholar 

  41. Donaldson SS, Moore MR, Rosenberg SA, Voski KL: Characterization of post splenectomy bacteraemia among patients with and without lymphoma. N Engl J Med, 1972; 287: 69–71.

    Article  PubMed  CAS  Google Scholar 

  42. Schimpff SC, O’Connell M7, Greene WH, Wiernik PH: Infections in 92 splenectomised patients with Hodgkin’s disease. Am J Med, 1975; 59: 695–701.

    Article  PubMed  CAS  Google Scholar 

  43. Weitzman SA, Aisenberg AC, Siber GR, Smith DH: Impaired humoral immunity in treated Hodgkin’s disease. N Engl J Med, 1977; 297: 245–48.

    Article  PubMed  CAS  Google Scholar 

  44. Donaldson SS, Kaplan HS: Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep, 1982; 66: 977–89.

    PubMed  CAS  Google Scholar 

  45. Fuks Z, Stroker S, Bobrove AM, Sasazuki T, McMichael A, Kaplan HS: Long term effects of radiation on T and B lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest, 1976; 58: 803–14.

    Article  PubMed  CAS  Google Scholar 

  46. Fisher RI, DeVita VT, Bostick F, Vanhaelen C, Houser DM, Hubbard SM, Young RC: Persistent immunologic abnormalities in long term survivors of advanced Hodgkin’s disease. Ann Intern Med, 1980; 92: 595–99.

    PubMed  CAS  Google Scholar 

  47. King GW, Grozea PC, Eyre HJ, LoBuglio AF: Neoantigen response in patients successfully treated for lymphoma: A Southwest Oncology Group Study. Ann Intern Med, 1979; 90: 892–95.

    PubMed  CAS  Google Scholar 

  48. Hancock BW, Bruce L, Whitham MD, Dunsmore IR, Ward AM, Richmond J: Immunity in Hodgkin’s disease: status after 5 years remission. Br J Cancer, 1982; 46: 593–600.

    Article  PubMed  CAS  Google Scholar 

  49. Colby TV, Hoppe RT, Warnke RA: Hodgkin’s disease at autopsy: 1972–1977. Cancer, 1981; 47: 1852–62.

    Article  PubMed  CAS  Google Scholar 

  50. Coltman CA Jr, Dixon DO: Malignancies complicating Hodgkin’s disease: A Southwest Oncology Group 10-year follow-up. Cancer Treat Rep, 1982; 66: 1023–33.

    PubMed  Google Scholar 

  51. Unger PF, Auderc G, Weil M, Jacquillat C: Tumeurs solides après traitement pour maladie de Hodgkin. Nouv Presse med, 1981; 10: 1463–67.

    PubMed  CAS  Google Scholar 

  52. Bodey GP, Bolivar R, Feinstein V: Infectious complications in leukaemic patients. Semin Hematol, 1982; 19: 193–226.

    PubMed  CAS  Google Scholar 

  53. Bodey GP, Buckley M, Sathe YS, Freireich EF: Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med, 1966; 64: 328–40.

    PubMed  CAS  Google Scholar 

  54. Baldwin RW, Embleton MI: Assessment of cell-mediated immunity to human tumour-associated antigens. Int Rev Exp Pathol, 1977; 17: 49–95.

    PubMed  CAS  Google Scholar 

  55. Hellström KE, Hellström I: Lymphocyte mediated cytotoxicity and blocking serum activity to tumour antigens. Adv Immunol, 1974; 18: 209–77.

    Article  PubMed  Google Scholar 

  56. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature, 1975; 256: 495–97.

    Article  PubMed  CAS  Google Scholar 

  57. Hellström KE, Hellström I, Braun JP: Human tumour-associated antigens identified by monoclonal antibodies. Springer Semin Immunopathol, 1982; 5: 127–46.

    Article  PubMed  Google Scholar 

  58. Baldwin RW, Flannery GR, Pelham JM, Dixon Gray J: Immunomodulation by IFN-conjugated monoclonal antibody to human osteogenic sarcoma. Proc Am Soc Clin Oncol, 1982; 23: 1003.

    Google Scholar 

  59. Kahan BD, Pellis NR, LeGrue SJ, Tanaka T: Immunotherapeutic effects of tumour specific transplantation antigens released by 1-butanol. Cancer, 1982; 49: 1163–73.

    Article  Google Scholar 

  60. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med, 1981; 306: 517–22.

    Article  Google Scholar 

  61. Fidler IJ, Poste G: Macrophage mediated destruction of malignant tumour cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol, 1982; 5: 161–74.

    Article  PubMed  CAS  Google Scholar 

  62. Fidler II, Raz A: The induction of tumoricidal capacities in mouse and rat macrophages by lymphokines. In: Lymphokines, Pick E (ed). New York, Academic Press, 1981: 345.

    Google Scholar 

  63. Russell SW, Gillespie GY, Pace JL: Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their non-specific cytotoxic capacities. Contemp Top Immunobiol, 1980; 10: 143–66.

    PubMed  CAS  Google Scholar 

  64. Eremin O, Coombs RR, Ashby J: Lymphocytes infiltrating human breast cancers lack NK cell activity and show low levels of NK cell activity. Br J Cancer, 1981; 44: 166–76.

    Article  PubMed  CAS  Google Scholar 

  65. Moore M, Vose BM: Extravascular natural cytotoxicity in man: anti-K562 activity of lymph node and tumour infiltrating lymphocytes. Int J Cancer, 1981; 27: 265–72.

    Article  PubMed  CAS  Google Scholar 

  66. Niitsuma M, Golub SH, Edelstein R, Carmack Holmes E: Lymphoid cells infiltrating human pulmonary tumours: effect of intralesional BCG injection. J Natl Cancer Inst, 1981; 67: 997–1004.

    PubMed  CAS  Google Scholar 

  67. Poste, Kirsh R: Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Cancer Res, 1979; 39: 2582–89.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. M. Rankin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. G. McVie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank, Groningen-Drenthe, The Netherlands

    P. C. Das  & C. Th. Smit Sibinga  & 

  2. Dept. of Haematology, University Hospital, Groningen, The Netherlands

    M. R. Halie

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers. Boston/Dordrecht/Lancaster

About this chapter

Cite this chapter

Rankin, E.M., McVie, J.G. (1985). Immunosuppression and oncology. In: Das, P.C., Sibinga, C.T.S., Halie, M.R. (eds) Supportive therapy in haematology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2577-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2577-2_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9617-1

  • Online ISBN: 978-1-4613-2577-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation